Kallio Anu, Guo Tao, Lamminen Elisa, Seppänen Jani, Kangas Lauri, Väänänen H Kalervo, Härkönen Pirkko
Institute of Biomedicine, Department of Anatomy, University of Turku, Tykistökatu 6 B, 20520 Turku, Finland.
Mol Cell Endocrinol. 2008 Jul 16;289(1-2):38-48. doi: 10.1016/j.mce.2008.03.005. Epub 2008 Mar 25.
In the current work, we compared the ability of 17beta-estradiol (E2) and the selective estrogen receptor modulators (SERMs), tamoxifen (Tam), raloxifene (Ral) and ospemifene (Osp) to promote the survival of osteoblast-derived cells against etoposide-induced apoptosis. In order to compare the roles of the two estrogen receptor (ER) isotypes, we created a U2OS human osteosarcoma cell line stably expressing either ERalpha (ERalpha) or ERbeta (ERbeta). Transfection with either of the ERs was able to render the U2OS cells sensitive to E2. We show that E2 opposed etoposide-induced apoptosis and that the effect was mediated via both ER isotypes. The ER isotype selective agonists propyl-pyrazole-triol (PPT) and diarylpropionitrile (DPN) had the same effect in U2OS/ERalpha and U2OS/ERbeta cells, respectively. Osp also opposed apoptosis at least in U2OS/ERalpha cells. Tam and Ral were not able to protect against etoposide-induced cell death. In order to evaluate the protective effects of E2 and Osp upon etoposide challenge, we studied the expression of two E2-regulated, osteoblast-produced cytokines, IL-6 and OPG in E2 and SERM-treated U2OS/ERalpha and U2OS/ERbeta cells. Etoposide strongly increased expression of IL-6 and decreased that of OPG. E2 opposed IL-6 increase only in U2OS/ERalpha cells and OPG decrease primarily in ERbeta cells. Osp opposed the effect of etoposide on OPG primarily in U2OS/ERbeta cells but interestingly, it had little effect on IL-6 expression. E2, PPT, DNP and Osp also inhibited etoposide-induced death and cytokine changes in SAOS-2 osteosarcoma cells expressing endogenous ERalpha and ERbeta. Collectively, our results suggest that the osteoblast protective anti-apoptotic effects of E2 are mediated by both ERalpha and ERbeta but those of Osp primarily by ERalpha. In addition, E2 and Osp opposed the etoposide-induced increase of IL-6 and decrease of OPG which changes would increase osteoclastic activity. These anti-resorptive effects of E2 and Osp upon etoposide challenge differed from each other and they seemed to be differentially mediated in ERalpha and ERbeta expressing osteoblast-derived U2OS cells.
在当前研究中,我们比较了17β-雌二醇(E2)以及选择性雌激素受体调节剂(SERM)他莫昔芬(Tam)、雷洛昔芬(Ral)和奥昔芬(Osp)促进成骨细胞来源细胞存活以抵抗依托泊苷诱导的细胞凋亡的能力。为了比较两种雌激素受体(ER)亚型的作用,我们构建了稳定表达ERα或ERβ的U2OS人骨肉瘤细胞系。用任一ER转染均能使U2OS细胞对E2敏感。我们发现E2可对抗依托泊苷诱导的细胞凋亡,且该效应是通过两种ER亚型介导的。ER亚型选择性激动剂丙基吡唑三醇(PPT)和二芳基丙腈(DPN)分别在U2OS/ERα和U2OS/ERβ细胞中具有相同作用。奥昔芬至少在U2OS/ERα细胞中也能对抗细胞凋亡。他莫昔芬和雷洛昔芬无法保护细胞免受依托泊苷诱导的细胞死亡。为了评估E2和奥昔芬在依托泊苷攻击下的保护作用,我们研究了两种E2调节的、成骨细胞产生的细胞因子白细胞介素-6(IL-6)和骨保护素(OPG)在E2和SERM处理的U2OS/ERα和U2OS/ERβ细胞中的表达。依托泊苷强烈增加IL-6的表达并降低OPG的表达。E2仅在UOS/ERα细胞中对抗IL-6的增加,主要在ERβ细胞中对抗OPG的降低。奥昔芬主要在U2OS/ERβ细胞中对抗依托泊苷对OPG的作用,但有趣的是,它对IL-6的表达几乎没有影响。E2、PPT、DPN和奥昔芬还抑制了表达内源性ERα和ERβ的SAOS-2骨肉瘤细胞中依托泊苷诱导的细胞死亡和细胞因子变化。总体而言,我们的结果表明,E2对成骨细胞的抗凋亡保护作用由ERα和ERβ共同介导,而奥昔芬主要由ERα介导。此外,E2和奥昔芬对抗依托泊苷诱导的IL-6增加和OPG降低,这些变化会增加破骨细胞活性。E2和奥昔芬在依托泊苷攻击下的这些抗吸收作用彼此不同,并且它们似乎在表达ERα和ERβ的成骨细胞来源的U2OS细胞中受到不同介导。